Member Info for lordloadsoflolly

cm22 - I do still hold TEK. Whether you believe me is of course down to you. And of no concern to me. TopCatz - sorry you find my comments weak & unconvincing. Sadly, the markets are siding with me rather than you at the moment. But having decided to hold for now still, I hope that changes.

No, because the presentation happened before this announcement! It's being appealed anyway, so who knows whether the takeover will actually end up being blocked. I suspect it will though.

TopCatz & Seamanp911 - There will be plenty of investors (like me) who bought in at higher levels. The share price has subsequently fallen (currently around 50% off this year's peak). So these aforementioned investors have 3 choices. Sell. Buy more to average down (potentially dangerous, as it concentrates a greater share of their portfolio into fewer companies) Or they remain convinced/hopeful of a re-rating within the next couple of years or so & stay put. I fall into that latter category currently. But it doesn't mean I think everything looks set for a multi-bagging any time soon. You ask me to give some reasons why not. So here's just three for you: a) TEK still lacks an even approximate timetable for any exit strategy & special dividend distribution for any of its major holdings. I don't expect them to say exactly when. Of course not. But until they give some rough indication (i.e. within the next 12-18 months, we expect to reduce investment in one or two of our current portfolio holdings and distribute this to shareholders via a special dividend), the discount to NAV is just likely to stay as it is or even worsen. b) There's already reasonable investor recognition of the potential in Guident, Bell & Microsalt . Lucyd not so much IMHO. Yet despite this, TEK's share price continues to flounder. Sure, part of this relates to the cyclical tech sector in general, where investor confidence is currently low. But I firmly believe part is also self-inflicted - see point a) above. c) Inflation ain't going away for another 12 months or so at least. And by definition, that's going to mean interest rates stay high and economies stagnate/recede. Not a great recipe for any share. But companies at the more speculative/growth end of the spectrum could fare worse than most in the short term at least.

Hello again TopCatz - I totally agree! Everyone's fully entitled to their opinions (and to post whatever they like - assuming it's not offensive). However, you've said you qualified your post. Afraid I can see absolutely nothing in your post that qualifies your unbridled optimism. Try reading it again (I attach it below), then please let us know exactly where you've qualified your comments: TOPCATZ - Tue 11.29: "They're a steal. Buy, tuck away, sit on hands and look forward to multi bagging next year. Everything on course here. Bell now manufacturing in China so should be pushing production, numbers to be released in the non too distant. Lucyd, can only really go one way. Not a lot of free float there. We saw it double form $1.50 to $3.00 just off the back of a corporate presentation ! Microsalt and Guident poised to add 10s of millions to the market cap. What's not to like about an entry point here !"

stocksr - no worries - & no need to stop posting either . It's always good to have a cross-section of views. I just prefer it when share price predictions are suitably qualified. After all, they're nothing more than a guess!

TopCatz - I'd just point that a lot of posters here have been saying that for some time (and when the share price was far higher than it is now). Not saying TEK doesn't have decent long term prospects, as I think (& hope) it might. But all this stuff about them being a steal/multibagging next year etc. etc. is just speculative nonsense.

stocksr - I very much doubt that, though I remain reasonably optimistic about SMT's long term (5 year +) prospects. Perhaps anyone else feeling it necessary to second-guess the future share price could make it clear it's just their opinion? Stating it as though it were fact is both misleading & potentially dangerous to the uninitiated.

lambo222 - And before you claim otherwise, your 30 Sept post was AFTER the FDA's response. The only significant RNS issued since then was on 11 Nov, stating: "Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities." Yet from being "very much game on", you've changed your tune to "No more than a cash shell". BUSTED.

lambo222 - you've clearly s short memory. Here's what you posted word for word on 30 Sept 2022: "AZN had sales of $1.2 billion in the first 6 months with their Lupus drug! Can you imagine where this could go from £9m Mcap once they get it approved… looks like the FDA are onboard and supportive, Avion are onboard and supportive and will find for $25m so it’s very much game on here, well done all that held big day ahead today that second rns was key as it shows FDA want to help the drug gain approval and Avion are happy to fund it, once finalised this will be back at 15p imo"

Apologies - my last post should of course read "Lupuzor".

I neither see today's RNS as hugely negative, nor wholly positive. It's somewhere in between for me. The good news is that Avion won't be pulling the plug on Lupozor. The bad news (which we already knew from the FDA's response) is that delays are baked in, even if Lupozor eventually gets to market. The possibly good news is that if IMM manages to distribute certain Avion products into Europe, it may not run out of cash for the time being. The possibly bad news is that the "legal, regulatory and commercial aspects of such a collaboration " are still under discussion. So this may not come to anything.

draft - not great. But then few stocks have been great over the past year or so. And don't forget you also gained "free" shares in PBX which become tradeable from end Dec. So that needs to be factored in.

It was a positive message. Now they just have to deliver.

Stoater - think you’ll find the 3x revenue plan is a 5 year target. So by 2027, not 2025. Still pretty ambitious though!

laallee - thanks for the interesting reference to Pershing Square. A fact sheet with more detailed info is available below. It has certainly performed well in recent years, but for me (given my other US-centric investments), it's too high risk. Might be worth a look for others though: https://api.fundinfo.com/document/e1dad6b5f6b704ed1707e5ad538fb287_152429/PRP_GB_en_GG00BPFJTF46_YES_2022-02-23.pdf

Beaub11 - Could well be, In which case recent Chinese stock rise likely to reverse soon.

SYN00GOLD - using bad, childish language simply shows you up. Again.

maidit308 - no-one was name calling. If someone says they can’t instantly buy any stock (implying demand outstrips supply), I think it’s only helpful to check & see if it’s a widespread issue. In such cases, I’ve nearly always found I’ve been able to trade instantly. So either Y-Alam’s Interactive platform has an issue, or it was just a momentary glitch. End of.

JRLOMAX - your constant bad language simply shows you up I'm afraid. Y-ALAM - which broker are you using? As I said, at around 11.10am today, mine gave me an instant quote & the option to buy immediately.

DorsetLSE - fair comment. That's always the risk. And as we all know, the past is no guide to the future. In terms of "where's the next Tesla?". Nobody can be sure of that in advance. After all, plenty thought Tesla was a pipedream 10 or 15 years ago. And Amazon before that. But SMT did alright out of them. I wouldn't write Moderna off just yet either. It IPO'd less than 4 years ago at $23 a share, so is still way above this price. Whilst it has fallen dramatically from its Sept 21 peak, interestingly, it's still above the level it traded at for most of 2020 when Covid first appeared. That to me suggests investors are increasingly waking up to Moderna's potential BEYOND Covid.